LYCA Insider Trading Activity and SEC Form 4 Filings
LYCA insider trading summary
Over the past 12 months, insiders at Lycia Therapeutics, Inc. (LYCA) reported 108 open-market purchases worth $346.7M by 9 insiders and no sales on SEC Form 4. Net insider buying was $346.7M.
Latest LYCA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | Venrock Healthcare Capital Partners XP, L.P. | 10% Owner | Buy | $224K (8,305 @ $26.95) |
| Nov 2, 2026 | Nimish P Shah | 10% Owner | Buy | $224K (8,305 @ $26.95) |
| Nov 2, 2026 | VHCP Management III, LLC | 10% Owner | Buy | $224K (8,305 @ $26.95) |
| Nov 2, 2026 | VHCP Management EG, LLC | 10% Owner | Buy | $224K (8,305 @ $26.95) |
| Nov 2, 2026 | VHCP Management XP, LLC | 10% Owner | Buy | $224K (8,305 @ $26.95) |
| Nov 2, 2026 | Bong Y Koh | 10% Owner | Buy | $224K (8,305 @ $26.95) |
| Nov 2, 2026 | Venrock Healthcare Capital Partners III, L.P. | Insider | Buy | $224K (8,305 @ $26.95) |
| Nov 2, 2026 | VHCP Co-Investment Holdings III, LLC | 10% Owner | Buy | $224K (8,305 @ $26.95) |
| Nov 2, 2026 | Venrock Healthcare Capital Partners EG, L.P. | 10% Owner | Buy | $224K (8,305 @ $26.95) |
| Oct 30, 2026 | Bong Y Koh | 10% Owner | Buy | $231K (8,804 @ $26.27) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.